Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960048 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL14748628 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL2830856 | 0.83 | TSHR (0.55) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL2828572 | 0.79 | TSHR (0.54) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL2826912 | 0.79 | TSHR (0.56) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL2826873 | 0.73 | SMN1; SMN2 (0.70) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL4998654 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL18589275 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL5001488 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 | |
| SCHEMBL2829245 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRLMNAHSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140004209-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004209-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | BECN1, SQSTM1, ULK1 | SMN1; SMN2 4206/4885TSHR 4088/4885LMNA 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.